SpinChip Diagnostics ASA

Transaction Valuation: SpinChip valued at NOK 1,624 million (EUR 138 million), making it one of the largest MedTech transactions in Norway. Menu Development: bioMérieux will accelerate the menu build-up of SpinChip’s Point of Care diagnostics platform. Strategic Growth: bioMérieux strengthens its position in the Point of Care market. Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million. Morten Jurs, Chief Executive Officer of SpinChip, stated: “The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to signif

With very high diagnostic accuracy, the SpinChip point-of-care (POC) test demonstrated performance comparable to the best-validated central laboratory-based assays. This excellent performance is a key factor in its potential to become a highly valuable tool in the early triage and management of patients with suspected Acute Myocardial Infarction (MI), providing reassurance and confidence in its use. The study set out to evaluate the clinical and analytical performance of SpinChip’s novel high-sensitivity cardiac troponin I (hs-cTnI)-SPINCHIP POC test and was carried out in collaboration with Basel University Hospital (Switzerland) and Akershus University Hospital (Norway). The SpinChip diagnostics platform is designed for scalability to become the broadest testing platform in the Point of Care market.

SpinChip Diagnostics has developed a small immunoassays Point of Care (POC) Analyzer that delivers the same diagnostics performance as most advanced lab instruments from a droplet of blood within minutes. The platform is scalable and has the potential to become the broadest testing platform in the POC market bioMérieux’s investment will advance SpinChip Diagnostics’ path to commercialisation